AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Financing Cash Flow · Q4 FY2024 · quarter ended Dec 2024
Financing cash flow of €81.86M in Q4 FY2024
Q4 FY2024 financing cash flow was €81.86M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
Currency unavailable · from the cash flow
No Financing Cash Flow data reported for this period type.
Financing Cash Flow vs competitors
How AGMB compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $360.93M USD | +53.0% | -72.7% | 4878.8% |
| LTM Mar 2026 | $102.81M USD | -191.7% | — | 44.2% | |
| LTM Mar 2026 | $65.68M USD | +25657.6% | — | — | |
| LTM Mar 2026 | $52.19M USD | -29.8% | — | 623.8% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | +11.6% | -72.7% | 623.8% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.